Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.

Authors :: Hayette S
Chabane K
Michallet M
Michallat E
Cony-Makhoul P
Salesse S
Maguer-Satta V
Magaud JP
Nicolini FE
Source :: Leukemia research [Leuk Res] 2011 Jan; Vol. 35 (1), pp. 38-43. Date of Electronic Publication: 2010 Jul 29.
Publication Year :: 2011
Abstract: This report aims to more accurately define the frequency of the involvement of SRC Family Kinases (SFKs) in imatinib- and dasatinib-resistant CML patients. Clinical samples were analysed during in vivo treatment. We confirmed the high frequency of SFKs involvement in Tyrosine kinase inhibitor-resistant CML (52% of the cases) and even further in progressive disease and blast crises (60% of the cases). The SFKs deregulation is also observed in patients harboring BCR-ABL mutations. In T315I and F317L mutated patients, CML-resistance appears to be promoted by SFKs kinase protein reactivation once the BCR-ABL mutated clone has decreased on Omacetaxine.<br /> (Copyright © 2010 Elsevier Ltd. All rights reserved.)

Subjects :: Base Sequence
Benzamides
Cell Line, Tumor
DNA Primers
Dasatinib
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl genetics
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive enzymology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Longitudinal Studies
Antineoplastic Agents therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Piperazines therapeutic use
Pyrimidines therapeutic use
Thiazoles therapeutic use
src-Family Kinases metabolism

Full Text Access

Tools